Moderna (MRNA) Cash & Current Investments (2017 - 2026)

Moderna has reported Cash & Current Investments for 10 years, with the latest figure at $5.1 billion in Q2 2026.

• Cash & Current Investments for Q2 2026 came in at $5.1 billion, changed 0.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.1 billion (changed 0.14% YoY), and the FY2025 annual result was $5.8 billion, down 17.45% from the prior year.
• Cash & Current Investments retreated to $5.1 billion in Q2 2026, from $5.2 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.1 billion in Q1 2022 and troughed at $4.5 billion in Q3 2025.
• A 5-year average of $7.4 billion and a median of $7.7 billion in 2022 frame the typical range for Cash & Current Investments.
• The widest annual swing landed in 2022, when Cash & Current Investments soared 30.77%; it then sank 39.55% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $9.9 billion in 2022, then dropped by 13.11% to $8.6 billion in 2023, then slipped by 18.35% to $7.0 billion in 2024, then fell by 17.45% to $5.8 billion in 2025, then declined by 11.4% to $5.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $5.1 billion in Q2 2026, $5.2 billion in Q1 2026, and $5.8 billion in Q4 2025.